SELLAS Life Sciences Group WKN: A2PU3T ISIN: US81642T2096 Forum: Aktien Thema: Hauptdiskussion

Denk das ein Langeweile push morgen dann wieder rot.

SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS in Greater China 12/07/20 Download this Press Release PDF Format (opens in new window) (PDF) - SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties - - 3D Medicines to Lead Clinical Development and Commercialization of G P S and GPS in Greater China - - SELLAS Retain s Rights in the Rest of World, Including U nited S tates - NEW YORK and SHANGHAI, Dec. 07, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, and 3D Medicines Inc. (“3DMed”), a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, today announced that they have entered into an Exclusive License Agreement granting rights to 3DMed to develop and commercialize SELLAS’ lead late-stage clinical candidate, galinpepimut-S (GPS), as well as its next generation heptavalent immunotherapeuatic, GPS , which is at preclinical stage, across all therapeutic and diagnostic uses in the Greater China territory (mainland China, Hong Kong, Macau and Taiwan). SELLAS retains sole rights to GPS and GPS outside of the Greater China area. Potential payments to SELLAS under the agreement could total $202 million in license fees and milestone payments, not including future royalties. GPS is an innovative potentially first-in-class WT1-targeting artificially engineered synthetic heteroclitic immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. In 2020, SELLAS commenced a Phase 3 clinical trial (the REGAL study) of GPS in patients with acute myeloid leukemia (AML) who have reached second complete remission. “This agreement represents an important achievement for SELLAS as we continue to progress our clinical development program for GPS. We are excited to collaborate with 3DMed on the development and commercialization of GPS in China. 3DMed, an ambitious biopharmaceutical company with development, registration and commercialization capabilities with a focus on developing next-generation immuno-oncology drugs and an experienced team, is a wonderfully complementary partner in bringing the potential of GPS to patients in Greater China. The collaboration begins to put in place essential elements designed to expand the reach of GPS outside the United States, following potential regulatory approvals," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “The completion of this agreement, amid the COVID-19 pandemic, shows the execution strength of our team. We are also pleased to have strengthened our balance sheet with the non-dilutive upfront license fee of $7.5 million with other potential milestones over the next several months.” “We are very pleased to execute this exclusive license agreement of GPS and GPS in the Greater China area with SELLAS,“ said John Gong, M.D., Ph.D., Chairman and Chief Executive Officer of 3DMed. “GPS and GPS are innovative therapeutics and, with growing need for new treatments, GPS’ potential use as a monotherapy as well as in combination with our Envafolimab, an innovative subcutaneous PD-L1 antibody which we have just filed for marketing approval in China, could create significant value for both 3DMed and SELLAS. This partnership highly reflects the vision of 3DMed to help patients with cancer to live longer and better. We believe that the addition of the GPS and GPS assets to our clinical portfolio is an important synergistic and strategic step for 3DMed as this partnership will expand our company’s therapeutic area expertise and improve our competitiveness.” Under the financial terms of the agreement: SELLAS could potentially receive up to $202 million in license and milestone payments during the course of the collaboration, not including future royalties. SELLAS will receive payment of an upfront license fee of $7.5 million payable this quarter and is eligible to receive potential near-term milestones totaling up to an additional $8.0 million. SELLAS is entitled to receive royalties on Chinese sales on a tiered basis, dependent on sales levels, ranging from the high single to low double-digit percentage. 3DMed will be responsible for the costs of all development and regulatory activity for Greater China.

Die bekommen irgend wann ja auch noch Ihre Meilenstein Zahlung von 200 Millionen Dollar wenn sie gewisse Ergebnisse nachweisen können.

Diamond Hands

Stock.Twits

AH Runner und die Wallstreetbets kommen

20$ morgen

Das knallt morgen richtig hier 🚀🚀

Bei *** wird von angeblichen bevorstehenden Phase Daten zu NPS schwadroniert.

@bewater, hast du eine Quelle für das auslaufen der Shorts?

https://www.nasdaq.com/market-activity/stocks/sls/after-hours-trades

Sonst keine news oder

Shorts laufen aus

Ui 🤩 9,30$ schon.

Was soll den noch kommen....

War bei 7,2